Chronic inflammation contributes to tumor promotion and progression, and many of the tumor-promoting effects of inflammation depend on the activation of the transcription factor NF-κB. Interference with NF-κB signalling therefore represents a potential new therapeutic approach. Our project concerns the study of how NF-kB-dependent inflammation affects intestinal tissue physiology and can contribute to the development of intestinal cancer.